## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.9% below STRENGTH zone (4.0-10.0%); PEG 2.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($83.11)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Why GE HealthCare is warning investors about this share offer**
- Source: Stock Titan | 20260106T220631 | Somewhat-Bearish | Relevance: 100%
- GE HealthCare is urging its shareholders to reject an unsolicited "mini-tender" offer from Potemkin Limited, citing a significantly-below-market price of $54.20 per share compared to GEHC's $83.09 closing price. The company warns that mini-tender offers typically lack the full disclosure and procedural protections of larger tender offers and advises investors to exercise caution. GE HealthCare is not affiliated with Potemkin Limited and recommends shareholders consult with financial advisors.

**2. GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026**
- Source: sharewise.com | 20260105T160823 | Neutral | Relevance: 100%
- GE HealthCare (Nasdaq: GEHC) is scheduled to announce its fourth-quarter and full-year 2025 financial results on Wednesday, February 4, 2026, before the market opens. Management will host a conference call and webcast on the same day at 8:30 a.m. Eastern Time to discuss the results. The earnings release and webcast replay will be accessible via the GE HealthCare Investor Relations website.

**3. GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026**
- Source: www.sharewise.com | 20260105T153759 | Neutral | Relevance: 100%
- GE HealthCare (NASDAQ: GEHC) announced it will release its fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, before market open. Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the results. The company, a global healthcare solutions provider with approximately 53,000 colleagues, was recognized among Fortune's 2025 Worldâ€™s Most Admired Companies.

**4. GE HealthCare warns investors about below-market mini-tender offer By Investing.com**
- Source: Investing.com | 20260106T221937 | Somewhat-Bearish | Relevance: 100%
- GE HealthCare Technologies Inc. (NASDAQ:GEHC) has warned investors about an unsolicited mini-tender offer from Potemkin Limited to purchase up to 100,000 shares at $54.20 each, which is approximately 34.77% below the market price. The company recommends shareholders reject the offer due to the significantly undervalued price and numerous conditions. GE HealthCare has no affiliation with Potemkin Limited and advises investors to seek financial advice and monitor market quotations.

**5. NXP and GE HealthCare partner on edge AI for medical applications**
- Source: Investing.com Canada | 20260106T161552 | Bullish | Relevance: 100%
- NXP Semiconductors and GE HealthCare have announced a partnership to develop edge artificial intelligence solutions for medical applications, prioritizing anesthesiology and neonatal care. This collaboration, unveiled at CES 2026, focuses on processing data directly on devices to enable faster response times and addresses privacy concerns by utilizing NXP's processors and AI Toolkit for local data handling. The conceptual technologies include voice-command capabilities for anesthesiologists and intelligent monitoring for neonatal care, though regulatory clearance and commercialization are not guaranteed.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | B of A Securiti | $92 | $82 | +12% |
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | B of A Securiti | main | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +3.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.46 elevated, pricing in significant growth expectations. Forward P/E 17.6x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.6B |
| Beta | 1.23 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.46 |
| Forward P/E | 17.6 |
| Current P/E | 19.0 |
| YoY Growth | 8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.2% to 2.9% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.1pp (needs >4.0% for momentum thesis). MRS_5 at 2.5% confirms short-term momentum alignment. AM_20 at 3.7% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.90% (CS: 67) | Neutral |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.092x | Above |
| vs SMA200 | 1.164x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.73
- **Stop Loss:** $83.11 (4.2% risk)
- **Target:** $90.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 364
- **Position Value:** $31,569.72
- **Portfolio %:** 31.57%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*